Syndax(美國(guó))

Syndax

Syndaxwww.syndax.comSyndax制藥專注于運(yùn)用表觀遺傳學(xué)相關(guān)的方法，克服在實(shí)體瘤治療中發(fā)生的耐藥性問題。公司擁有Entinostat在全球的專利權(quán)。Entinostat是一種口服的、高選擇性的組蛋白去乙酰化酶（HDAC）抑制劑，用于晚期乳腺癌和肺癌的臨床治療。同樣在一組非小細(xì)胞肺癌患者的治療中（ENCORE401），Entinostat與EGFR-TKI厄洛替尼配合使用也取得了 積極有效的結(jié)果。美國(guó)國(guó)家癌癥研究所（NCI）和Syndax制藥就Entinostat的發(fā)展達(dá)成了合作研究和開發(fā)協(xié)議，旨在改善晚期癌癥和難治性癌癥的存活率。Syndaxisfocusedonemployingepigeneticstrategiestoovercometheproblemofresistanceinoncologycareinsolidtumors.Thecompanyholdsworldwiderightstoentinostat,anoral,highlyselectivehistonedeacetylase(HDAC)inhibitorinlate-stageclinicaldevelopmentforthetreatmentofadvancedbreastcancerandlungcancer.Arandomized,placebo-controlledPhase2studyofentinostatincombinationwitharomataseinhibitorsinbreastcancer(ENCORE301)demonstratedanimprovementinbothprogression-freesurvivalandoverallsurvival,providingthebasisfortheevaluationofentinostatinpivotalPhase3testinginmetastaticbreastcancer.Entinostatalsodemonstratedpromis